Spots Global Cancer Trial Database for A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
Official Title: A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies
Study ID: NCT02223598
Study Description
Brief Summary: The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope National Medical Center, Duarte, California, United States
University of California, San Francisco, San Francisco, California, United States
Emory University, Atlanta, Georgia, United States
RCCA MD, Bethesda, Maryland, United States
Washington University, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Cedars Cancer Centre, McGill University Health Centre, Montreal, Quebec, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
